Catalog No.
Product Name
Application
Product Information
Citations
-
JNK inhibitor
SP600125 is a JNK inhibitor with IC50=40 nM for JNK-1 and JNK-2 and 90 nM for JNK-3.- Peiling Zhang, .et al. , Regen Biomater, 2023, Sep 7:10:rbad079 PMID: 38020237
- Tetsuya Kouno, .et al. , J Biol Chem, 2022, Jul;298(7):102056 PMID: 35605662
- Mark P Roberto, .et al. , Immunity, 2021, Aug 10;54(8):1807-1824.e14 PMID: 34380064
- Yang PM, .et al. , Am J Cancer Res, 2019, Oct 1;9(10):2120-2139 PMID: 31720078
- Byungki Jang, .et al. , Int J Mol Sci, 2017, Nov; 18(11): 2258 PMID: 29077055
- Yuki Haga, .et al. , PLoS One, 2017, 12(3): e0174153 PMID: 28323861
- Jia-Shiuan Tsai, .et al. , PLoS One, 2016, 11(1): e0147011 PMID: 26751215
- Choe YJ, .et al. , Int J Oncol., 2014, 44(3):761-8. PMID: 24366007
-
SAPKs/JNKs activator
Anisomycin is a pyrrolidine antibiotic, acts as an anti-fungal antibiotic which inhibits Protein Synthesis, also is a potent activator of SAPKs/JNKs.- Ken Kobayashi, .et al. , Cell Tissue Res, 2022, Sep;389(3):501-515 PMID: 35748981
- Li Li, .et al. , Cancer Cell Int, 2021, May 13;21(1):260 PMID: 33985519
-
JNK inhibitor
AS 602801 is a novel, orally active, Jun Kinase Inhibitor.- Shuai Zhang, .et al. , J Cell Mol Med, 2021, Apr;25(8):4062-4072 PMID: 33609076
- Kuramoto K, .et al. , Anticancer Res, 2018, Sep;38(9):5093-5099 PMID: 30194154
-
JNK inhibitor
CC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity.- Jacob Insua‐Rodriguez, .et al. , EMBO Mol Med, 2018, Oct; 10(10): e9003 PMID: 30190333
-
JNK Inhibitor IX
TCS JNK 5a is a highly selective inhibitor of JNK2 and JNK3 (pIC50 values are 6.7, 6.5, <5.0 and <4.8 for JNK3, JNK2, JNK1 and p38α respectively).
-
JNK Inhibitor
JNK-IN-8 is the first irreversible JNK inhibitor for JNK1, JNK2 and JNK4 with IC50 of 4.7 nM, 18.7 nM and 1 nM, respectively- Mark P Roberto, .et al. , Immunity, 2021, Aug 10;54(8):1807-1824.e14 PMID: 34380064
-
JNK inhibitor
CC-930 is kinetically competitive with ATP in the JNK-dependent phosphorylation of the protein substrate c-Jun and potent against all isoforms of JNK (Ki(JNK1) = 44 ?? 3 nM, IC50(JNK1) = 61 nM, Ki(JNK2) = 6.2 ?? 0.6 nM, IC50(JNK2) = 5 nM, IC50(JNK3) = 5 nM) and selective against MAP kinases ERK1 and p38a with IC50 of 0.48 and 3.4 μM respectively -
JNK inhibitor
CC-401 hydrochloride is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity. -
MKK4-dependent macropinocytotic Activator
Vacquinol-1 is an MKK4 activator, which rapidly and selectively induces glioma cell death. -
JNK inhibitor
JIP-1 (153-163) is a peptide inhibitor of c-Jun N-terminal kinase (JNK), based on residues 153-163 of JNK-interacting protein-1 (JIP-1). Binds to JNK with affinity in the micromolar range and minimally inhibits p38 and ERK. -
JNK inhibitor
c-JUN peptide is a peptide comprising residues 33 - 57 of the JNK binding (δ) domain of human c-Jun. -
JNK inhibitor
TCS JNK 6o is a ATP-competitive and selective c-Jun N-terminal kinase (JNK) inhibitor. -
JNK3 inhibitor
IQ-1S is a Selective JNK3 inhibitor with IC50 value of 390, 360 and 87 nM for JNK1, 2 and 3 respectively. - Guggulsterone is a plant sterol derived from the gum resin of the tree Commiphora wightii. Guggulsterone inhibits the growth of a wide variety of tumor cells and induces apoptosis through down regulation of antiapoptotic gene products (IAP1, xIAP, Bfl-1/A1, Bcl-2, cFLIP and survivin), modulation of cell cycle proteins (cyclin D1 and c-Myc), activation of caspases and JNK, inhibition of Akt.
-
Autophagy inducer
Tomatidine hydrochloride acts as an anti-inflammatory agent by blocking NF-κB and JNK signaling. Tomatidine hydrochloride activates autophagy either in mammal cells or C elegans. -
NF-κB inhibitor
Urolithin B is one of the gut microbial metabolites of ellagitannins, and has anti-inflammatory and antioxidant effects. Urolithin B is also a regulator of skeletal muscle mass. -
antiinflammation agent
Ginsenoside Re (Ginsenoside B2) is an extract from Panax notoginseng. Ginsenoside Re decreases the β-amyloid protein (Aβ). Ginsenoside Re plays a role in antiinflammation through inhibition of JNK and NF-κB. -
JNK inhibitor
CC-90001 is a potent and selective JNK inhibitor. CC-90001 shows 12.9-fold selectivity for JNK1 over JNK2 in a cell-based model. CC-90001 can be used for the research of idiopathic pulmonary fibrosis -
PPAR agonist
Lobeglitazone sulfate is a novel thiazolidinedione and an orally active agonist of peroxisome proliferator-activated receptors (PPARs), with EC50 values of 137.4 nM for PPARγ and 546.3 nM for PPARα. It also acts as an inhibitor of the ERK/JNK/Smad/NF-κB signaling pathways. Lobeglitazone sulfate exhibits anti-inflammatory, anti-diabetic, anti-fibrotic, and anti-atherosclerotic activities, supporting its potential in the treatment of metabolic and inflammatory diseases. - 6-Demethoxytangeretin is a flavonoid compound isolated from *Citrus reticulata* with demonstrated anti-inflammatory and anti-allergic properties. It inhibits IL-6 production and the expression of related genes in human mast cells by modulating the ALK and MAPK signaling pathways. Additionally, 6-Demethoxytangeretin enhances CRE-mediated transcription in hippocampal neurons, indicating potential neuroregulatory effects.
-
Endoplasmic Reticulum Stress Inhibitor
Tauroursodeoxycholate (Tauroursodeoxycholic acid; TDUCA) dihydrate is an inhibitor of endoplasmic reticulum (ER) stress that significantly downregulates pro-apoptotic molecules, including caspase-3 and caspase-12. Additionally, it suppresses ERK signaling, contributing to its cytoprotective and anti-apoptotic effects. -
Neuroprotective agent
(E)-Osmundacetone is a geometric isomer of Osmundacetone, exhibiting notable biological activity. It significantly inhibits the phosphorylation of mitogen-activated protein kinases (MAPKs), including JNK, ERK, and p38, which are key mediators of cellular stress and inflammatory responses. Through this inhibition, (E)-Osmundacetone exerts neuroprotective effects, particularly against oxidative stress-induced neuronal damage. These properties make it a promising compound for research in neurodegenerative diseases and oxidative stress-related conditions. -
PPAR agonist
Lobeglitazone is a novel thiazolidinedione-class compound and an orally active dual agonist of peroxisome proliferator-activated receptors (PPARs), with EC₅₀ values of 137.4 nM for PPARγ and 546.3 nM for PPARα. In addition to its metabolic effects, Lobeglitazone functions as an inhibitor of multiple pro-inflammatory and pro-fibrotic signaling pathways, including ERK, JNK, Smad, and NF-κB. Lobeglitazone exhibits a broad range of pharmacological activities, including anti-inflammatory, anti-diabetic, anti-fibrotic, and anti-atherosclerotic effects. These properties make it a promising candidate for therapeutic research in metabolic syndrome, type 2 diabetes, cardiovascular disease, and fibrosis-related conditions. - 6-Hydroxyflavone is an orally active flavonoid with diverse pharmacological properties. It exhibits anti-inflammatory activity by inhibiting lipopolysaccharide (LPS)-induced nitric oxide (NO) production and also promotes osteoblast differentiation through activation of the AKT, ERK1/2, and JNK signaling pathways, supporting its role in bone health. Additionally, 6-Hydroxyflavone inhibits the glycosylation of bovine hemoglobin (BHb), suggesting potential in managing glycation-related complications. It demonstrates kidney-protective effects and modulates GABAergic neurotransmission by enhancing GABA-induced currents via the benzodiazepine binding sites on GABAA receptors
-
Endogenous Metabolite
Gamma-linolenic acid (γ-linolenic acid, GLA) is an orally active omega-6 unsaturated fatty acid with broad pharmacological activities. It exhibits anti-inflammatory effects by inhibiting the NF-κB signaling pathway and suppressing the phosphorylation of ERK1/2 and JNK, key mediators of inflammatory responses. GLA also induces apoptosis in cancer cells, contributing to its anticancer potential. Additionally, it possesses antioxidant properties and has been shown to improve memory function, suggesting neuroprotective benefits. These multifunctional effects position gamma-linolenic acid as a promising compound for research in inflammation, oncology, and neurological disorders. -
Microglial inhibitor
Inflachromene is a microglial inhibitor that exerts anti-inflammatory effects by directly binding to high mobility group box proteins HMGB1 and HMGB2. Through this interaction, it effectively downregulates the proinflammatory activities of HMGB proteins, leading to reduced microglial activation and neuronal damage. Inflachromene holds promise as a therapeutic candidate for the treatment of neuroinflammatory disorders, including neurodegenerative diseases and central nervous system injuries. -
BMP receptor agonist
SY-LB-35 is a potent agonist of bone morphogenetic protein (BMP) receptors, capable of activating both canonical and non-canonical signaling pathways. In the C2C12 myoblast cell line, SY-LB-35 significantly enhances cell proliferation and viability, promoting cell cycle progression by increasing the proportion of cells in the S and G2/M phases. Mechanistically, it activates the canonical Smad pathway as well as non-canonical PI3K/Akt, ERK, p38, and JNK signaling cascades. These properties make SY-LB-35 a valuable tool for studying BMP-related cellular processes and a potential therapeutic candidate for tissue regeneration and muscle repair. -
CDK Inhibitor
Aloisine A is a potent cyclin-dependent kinase (CDK) inhibitor, exhibiting IC50 values of 0.15 μM for CDK1/cyclin B, 0.12 μM for CDK2/cyclin A, 0.4 μM for CDK2/cyclin E, and 0.16 μM for CDK5/p35. In addition to its CDK inhibitory effects, Aloisine A also inhibits GSK-3α and GSK-3β with IC50 values of 0.5 μM and 1.5 μM, respectively. Notably, it enhances the activity of wild-type and mutant CFTR with submicromolar affinity through a cAMP-independent mechanism, making it a valuable tool for research related to cystic fibrosis and CFTR-related disorders. -
Apoptosis Inducer
epi-Eriocalyxin A is a diterpenoid compound that serves as an apoptosis inducer in colon cancer cells. It effectively inhibits the activation of ERK1/2 and JNK pathways, leading to the suppression of Bcl-2 expression. This compound is valuable for research focused on cancer treatment and the mechanisms of apoptosis. -
Antiviral Agent
Dendrobine is an alkaloid derived from Dendrobium nobile, primarily targeting viral infections as an antiviral agent. It demonstrates significant antiviral activity against influenza A viruses, exhibiting IC50 values of 3.39 μM, 2.16 μM, and 5.32 μM for strains A/FM-1/1/47 (H1N1), A/Puerto Rico/8/34 H274Y (H1N1), and A/Aichi/2/68 (H3N2), respectively. Additionally, Dendrobine activates the JNK/p38/Nrf2 signaling pathway and possesses various biological properties, including antitumor, anti-inflammatory, and neuroprotective effects, making it valuable in diverse research applications. -
Anticancer Agent
Citropten, also known as 5,7-dimethoxycoumarin, is a coumarin derivative with notable anticancer properties. It demonstrates significant anti-proliferative effects against A2058 and B16 melanoma cell lines, making it a valuable tool in cancer research. Additionally, Citropten exhibits anti-inflammatory activity by modulating the NFκB and MAPK signaling pathways. Its potential antidepressant effects are mediated through interactions with heat shock protein-70, monoamine oxidase-A, and the inhibition of apoptosis. -
MKK7-JNK Activator
MKK7-JNK Activator 1 is a potent activator of the MKK7-JNK signaling pathway. This compound effectively inhibits the proliferation and migration of MDA-MB-468 cells, while also triggering G2/M phase cell cycle arrest and caspase-dependent apoptosis, independent of reactive oxygen species (ROS) production. Notably, MKK7-JNK Activator 1 significantly increases the phosphorylation levels of MKK7 and JNK without affecting ERK or p38 phosphorylation. This reagent is valuable for studying mechanisms relevant to triple-negative breast cancer (TNBC). -
JNK Inhibitor
(3S)-Tanzisertib hydrochloride is a selective inhibitor of c-Jun N-terminal kinases (JNK), demonstrating IC50 values of 61, 7, and 6 nM for JNK1, JNK2, and JNK3, respectively. This compound also exhibits inhibition of ERK1, p38α, and EGFR with IC50 values of 0.48, 3.4, and 0.38 μM, respectively. (3S)-Tanzisertib hydrochloride effectively reduces LPS-induced TNFα production in an acute rat pharmacokinetic-pharmacodynamic model, making it a valuable tool in idiopathic pulmonary fibrosis research and other inflammatory disease studies. -
JNK/c-Jun Activator
Ophiopogonin B primarily activates the JNK/c-Jun signaling pathway. This saponin compound, derived from Radix Ophiopogonjaponicus, demonstrates significant biological activity by inducing autophagy and apoptosis in colon cancer cells. It serves as a valuable reagent for researchers investigating mechanisms of cancer cell death and the therapeutic potential of autophagy modulation. -
JNK Inhibitor, ERK Inhibitor, TGFβ signaling Activator
(+)-Columbianetin targets JNK and ERK signaling pathways while acting as a TGFβ signaling activator. This compound effectively inhibits UVA-induced phosphorylation of JNK and ERK, decreases MMP-1 production, and reverses collagen degradation. In addition, it mitigates UVA-mediated suppression of Smad2/3 phosphorylation and translocation, providing protective effects against UV-induced cellular damage. (+)-Columbianetin is an essential tool for research focused on skin aging and oxidative stress responses in keratinocytes. -
p38/JNK Inhibitor
LL-Z1640-4 is a selective inhibitor of p38 and JNK signaling pathways, demonstrating significant efficacy in attenuating their activation in hepatocellular carcinoma (HCC) cells following MLK4 siRNA transfection. This compound effectively reduces reactive oxygen species (ROS) production associated with MLK4 knockdown and subsequently decreases apoptosis in these HCC cells. LL-Z1640-4 serves as a valuable tool for investigating the roles of p38 and JNK in cancer biology and therapeutic interventions. -
JNK Acticator
Juglanin is a naturally occurring flavonoid isolated from Polygonum aviculare, primarily acting as a JNK activator. It exhibits significant anti-inflammatory, antioxidant, and antitumor properties. Research indicates that Juglanin induces apoptosis and promotes autophagy in human breast cancer cells, making it a valuable reagent for studies on cancer biology and therapeutic interventions. -
JNK Activator
BDE 47 is a JNK activator that targets mitochondria to inhibit mitochondrial oxidative phosphorylation (OXPHOS). This compound decreases mitochondrial membrane potential (MMP) and induces apoptosis in embryonic cells. Additionally, BDE 47 triggers the generation of reactive oxygen species (ROS) and activates the JNK signaling pathway, demonstrating embryonic developmental toxicity in zebrafish models. Its unique properties make it a valuable tool for research on oxidative stress and developmental biology. -
JNK Inhibitor
JNK-IN-17 is a selective and potent inhibitor of c-Jun N-terminal kinase (JNK), demonstrating IC50 values of 0.039 μM and 0.079 μM for JNK1 and JNK3, respectively. It effectively inhibits c-Jun phosphorylation with an IC50 of 0.082 μM in Streptozotocin-induced INS-1 pancreatic islet β cells. Additionally, JNK-IN-17 exhibits low interaction potential, showing an inhibition rate of ≤ 33% on major cytochrome P450 subtypes in human liver microsomes. This compound is valuable for research applications related to neurological and metabolic disorders, including Parkinson's disease. -
JNK Inhibitor
Cyy-272 is a potent orally active inhibitor of c-Jun N-terminal kinase (JNK), exhibiting IC50 values of 1.25 μM for JNK1, 1.07 μM for JNK2, and 1.24 μM for JNK3. This compound demonstrates significant anti-inflammatory properties by inhibiting JNK phosphorylation, effectively mitigating acute lung injury induced by lipopolysaccharide. Additionally, Cyy-272 reduces inflammation in cardiomyocytes and cardiac tissues affected by high lipid concentrations, contributing to decreased cardiac hypertrophy, fibrosis, and apoptosis. It is valuable for research into the mechanisms of obese cardiomyopathy and related cardiovascular disorders.
